Spots Global Cancer Trial Database for opdivo
Every month we try and update this database with for opdivo cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. | |
| Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment | NCT04875611 | Nasopharyngeal ... | Opdivo | 18 Years - | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | NCT03181308 | Carcinoma, Non-... | Carotuximab (TR... OPDIVO | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | NCT04963283 | Colorectal Aden... Colon Cancer Colon Adenocarc... Rectum Cancer Rectal Cancer Rectal Adenocar... Colorectal Canc... | Cabozantinib Nivolumab | 18 Years - | University of Colorado, Denver | |
| Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | NCT03650894 | Breast Neoplasm... Breast Cancer Breast Carcinom... Breast Tumor | Nivolumab Ipilimumab Bicalutamide | 18 Years - | Providence Health & Services | |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread | NCT04810078 | Clear Cell Rena... | Nivolumab and r... Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | NCT05004025 | Uveal Melanoma | Novocure Optune Opdivo Yervoy | 18 Years - 100 Years | HonorHealth Research Institute | |
| A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | NCT06112808 | Advanced Melano... | BCD-263 Opdivo | 18 Years - | Biocad | |
| A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | NCT05005273 | Non-Small Cell ... | Nivolumab Ipilimumab BMS-986207 Placebo | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | NCT03993353 | Head and Neck C... Head and Neck S... Head and Neck C... Head and Neck C... Head and Neck C... Head and Neck C... Cancer Cancer of Esoph... Cancer, Metasta... Cancer of Head ... Cancer of Mouth Cancer of Neck | Pembrolizumab Tadalafil | 18 Years - | University of California, San Diego | |
| Neoadjuvant Immunotherapy in Brain Metastases | NCT04434560 | Brain Metastase... | Nivolumab Ipilimumab | 18 Years - | Duke University | |
| A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | NCT04731467 | Solid Tumor Non Small Cell ... Pancreatic Canc... Ovarian Cancer Papillary Thyro... Melanoma Colorectal Aden... | CM-24 and Nivol... CM-24, Nivoluma... CM-24, Nivoluma... Nivolumab, Nab ... Nivolumab and N... | 18 Years - | Purple Biotech Ltd. | |
| Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | NCT02950038 | Lung Cancer, No... | Ibrutinib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | NCT02426892 | Solid Tumors | ISA 101 Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT02812667 | Non-small Cell ... | Nivolumab + Pli... | 18 Years - | University of California, San Diego | |
| Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer | NCT03433534 | Kidney Cancer Lung Cancer | Pharmacokinetic... | 18 Years - | University Hospital, Tours | |
| Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A | NCT03245021 | Follicular Lymp... | Opdivo | 18 Years - | Austin Health | |
| Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | NCT03656627 | Autoimmune Dise... Non-small Cell ... Rheumatoid Arth... Psoriasis Giant Cell Arte... Polymyalgia Rhe... Systemic Lupus ... Crohn Disease Multiple Sclero... Ulcerative Coli... | Nivolumab | 18 Years - | Alliance Foundation Trials, LLC. | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | NCT04943900 | Advanced Solid ... | BMS-986416 Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | NCT06112808 | Advanced Melano... | BCD-263 Opdivo | 18 Years - | Biocad | |
| Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | NCT04627012 | Hepatocellular ... Anti-PD1 Antibo... Liver Diseases | Lenvatinib Opdivo Camrelizumab Keytruda Toripalimab Sintilimab Tislelizumab | 18 Years - 75 Years | Sun Yat-sen University | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | NCT02812667 | Non-small Cell ... | Nivolumab + Pli... | 18 Years - | University of California, San Diego | |
| Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC) | NCT02950038 | Lung Cancer, No... | Ibrutinib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | NCT03241186 | Mucosal Melanom... | Ipilimumab Nivolumab Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | NCT02842125 | Metastatic Soli... Recurrent Head ... | Ad-P53 Xeloda Keytruda Opdivo | 18 Years - | MultiVir, Inc. | |
| An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | NCT03029780 | Renal Cell Carc... | Opdivo Yervoy | 18 Years - | Bristol-Myers Squibb | |
| Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | NCT02464657 | Leukemia Acute Myeloid L... Myelodysplastic... | Nivolumab Idarubicin Cytarabine Solu-medrol Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | NCT05005273 | Non-Small Cell ... | Nivolumab Ipilimumab BMS-986207 Placebo | 18 Years - | Bristol-Myers Squibb | |
| Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer | NCT04258150 | Pancreatic Canc... | Nivolumab Ipilimumab Tocilizumab SBRT | 18 Years - | Herlev Hospital | |
| Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | NCT03241186 | Mucosal Melanom... | Ipilimumab Nivolumab Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy | NCT06304597 | Locally Advance... | Imfinzi Opdivo | 18 Years - | University Medical Center Groningen | |
| Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | NCT03297593 | Renal Cell Carc... | nivolumab ipilimumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors. | NCT04761198 | Solid Tumor, Ad... Advanced Solid ... Metastatic Soli... | Etigilimab dosi... Nivolumab | 18 Years - | Mereo BioPharma | |
| Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors | NCT02426892 | Solid Tumors | ISA 101 Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | NCT03029780 | Renal Cell Carc... | Opdivo Yervoy | 18 Years - | Bristol-Myers Squibb | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | NCT03283046 | Malignant Neopl... Multiple Myelom... | Nivolumab Lenalidomide Dexamethasone Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma | NCT05002569 | Melanoma | Nivolumab Nivolumab + Rel... | 12 Years - | Bristol-Myers Squibb | |
| Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A | NCT03245021 | Follicular Lymp... | Opdivo | 18 Years - | Austin Health |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
